RFS according to subgroup.
death
DISEASE, RECURRENCE, SECONDARY
Shown is a forest plot of unstratified HRs (estimated using an unstratified Cox proportional hazards model) for disease recurrence or death among subgroups of patients. Circles indicate HRs among subgroups of patients, horizontal lines indicate corresponding 95% CIs and the vertical dotted line indicates the HR for the overall population. Improvement was also observed with adjuvant nivolumab for the key secondary endpoint of distant metastasis-free survival (DMFS), with 8.0% (42/526) of patients in the nivolumab group and 15.5% (41/264) of patients in the placebo group experiencing distant recurrence or death, with an HR of 0.47 (95% CI: 0.30–0.72) for the intention-to-treat population (Fig. 